1932

Abstract

The burden of hepatocellular carcinoma (HCC), the most common form of liver cancer, is steadily growing because obesity, type 2 diabetes, and nonalcoholic fatty liver disease (NAFLD) are replacing viral- and alcohol-related liver disease as major pathogenic promoters. The most worrisome aspects of these new risk factors are their large spread in the general population and their link with HCC arising in noncirrhotic livers. HCC may be the presenting feature of an asymptomatic nonalcoholic steatohepatitis (NASH), the progressive form of NAFLD. The HCC risk connected to metabolic factors has been underestimated so far, and a poorer surveillance has prevented an adequate treatment. Systemic and hepatic molecular mechanisms involved in obesity- and NAFLD-induced hepatocarcinogenesis as well as potential early markers of HCC are being extensively investigated. This review summarizes current evidence linking obesity, NAFLD and liver cancer, discusses its clinical impact and describes the main mechanisms underlying this complex relationship.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-med-090514-013832
2016-01-14
2024-04-16
Loading full text...

Full text loading...

/deliver/fulltext/med/67/1/annurev-med-090514-013832.html?itemId=/content/journals/10.1146/annurev-med-090514-013832&mimeType=html&fmt=ahah

Literature Cited

  1. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. 1.  2003. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S adults. N. Engl. J. Med. 348:1625–38 [Google Scholar]
  2. Altekruse SF, McGlynn KA, Reichman ME. 2.  2009. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J. Clin. Oncol. 27:1485–91 [Google Scholar]
  3. Marrero JA, Fontana RJ, Su GL. 3.  et al. 2002. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 36:1349–54 [Google Scholar]
  4. Lazo M, Clark JM. 4.  2008. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin. Liv. Dis. 28:339–50 [Google Scholar]
  5. Argo CK, Caldwell SH. 5.  2009. Epidemiology and natural history of non-alcoholic steatohepatitis. Clin. Liver. Dis. 13:511–31 [Google Scholar]
  6. Chalasani N, Younossi Z, Lavine JE. 6.  et al. 2012. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55:2005–23 [Google Scholar]
  7. Baffy G, Brunt EM, Caldwell SH. 7.  2012. Hepatocellular carcinoma in nonalcoholic fatty liver disease: an emerging menace. J. Hepatol. 56:1384–91 [Google Scholar]
  8. Wolk A, Gridley G, Svensson M. 8.  et al. 2001. A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control 12:13–21 [Google Scholar]
  9. Nair S, Mason A, Eason J. 9.  et al. 2002. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis?. Hepatology 36:150–55 [Google Scholar]
  10. Batty GD, Shipley MJ, Jarrett RJ. 10.  et al. 2005. Obesity and overweight in relation to organ-specific cancer mortality in London (UK): findings from the original Whitehall study. Int. J. Obes. 29:1267–74 [Google Scholar]
  11. Oh SW, Yoon YS, Shin SA. 11.  2005. Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study. J. Clin. Oncol. 23:4742–54 [Google Scholar]
  12. Samanic C, Chow WH, Gridley G. 12.  et al. 2006. Relation of body mass index to cancer risk in 362,552 Swedish men. Cancer Causes Control 17:901–9 [Google Scholar]
  13. Borena W, Strohmaier S, Lukanova A. 13.  et al. 2012. Metabolic risk factors and primary liver cancer in a prospective study of 578,700 adults. Int. J. Cancer 131:193–200 [Google Scholar]
  14. Schlesinger S, Aleksandrova K, Pischon T. 14.  et al. 2013. Abdominal obesity, weight gain during adulthood and risk of liver and biliary tract cancer in a European cohort. Int. J. Cancer 132:645–57 [Google Scholar]
  15. Larsson SC, Wolk A. 15.  2007. Overweight, obesity and risk of liver cancer: a metaanalysis of cohort studies. Br. J. Cancer 97:1005–8 [Google Scholar]
  16. Chen CL, Yang HI, Yang WS. 16.  et al. 2008. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 135:111–21 [Google Scholar]
  17. Inoue M, Iwasaki M, Otani T. 17.  et al. 2006. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch. Intern. Med. 166:1871–77 [Google Scholar]
  18. Davila JA, Morgan RO, Shaib Y. 18.  et al. 2005. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 54:533–39 [Google Scholar]
  19. El-Serag HB, Tran T, Everhart JE. 19.  2004. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 126:460–68 [Google Scholar]
  20. Polesel J, Zucchetto A, Montella M. 20.  et al. 2009. The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma. Ann. Oncol. 20:353–57 [Google Scholar]
  21. Wideroff L, Gridley G, Mellemkjaer L. 21.  et al. 1997. Cancer incidence in a population based color of patients hospitalized with diabetes mellitus in Denmark. J. Natl. Cancer Inst. 89:1360–65 [Google Scholar]
  22. Noto H, Osame K, Sasazuki T, Noda M. 22.  2010. Substantially increased risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis of epidemiologic evidence in Japan. J. Diabetes Complicat. 24:345–53 [Google Scholar]
  23. Adams LA, Lymp JF, St Sauver J. 23.  et al. 2005. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129:113–21 [Google Scholar]
  24. Sanyal A, Poklepovic A, Moyneur E, Barghout V. 24.  2010. Population-based risk factors and resource utilization for HCC: US perspective. Curr. Med. Res. Opin. 26:2183–91 [Google Scholar]
  25. Matteoni CA, Younossi ZM, Gramlich T. 25.  et al. 1999. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116:1413–19 [Google Scholar]
  26. Ekstedt M, Franzen LE, Mathiesen UL. 26.  et al. 2006. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44:865–73 [Google Scholar]
  27. Yatsuji S, Hashimoto E, Tobari M. 27.  et al. 2009. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J. Gastroenterol. Hepatol. 24:248–54 [Google Scholar]
  28. Sanyal AJ, Banas C, Sargeant C. 28.  et al. 2006. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 43:682–89 [Google Scholar]
  29. Bhala N, Angulo P, van der Poorten D. 29.  et al. 2011. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 54:1208–16 [Google Scholar]
  30. Dyson J, Jaques B, Chattopadyhay D. 30.  et al. 2014. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J. Hepatol. 60:110–17 [Google Scholar]
  31. Regimbeau JM, Colombat M, Mognol P. 31.  et al. 2004. Obesity and diabetes as a risk factor for hepatocellular carcinoma. Liver Transpl. 10:S69–73 [Google Scholar]
  32. Bugianesi E, Leone N, Vanni E. 32.  et al. 2002. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 123:134–40 [Google Scholar]
  33. Paradis V, Zalinski S, Chelbi E. 33.  et al. 2009. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 49:851–59 [Google Scholar]
  34. Tokushige K, Hashimoto E, Horie Y. 34.  et al. 2011. Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease, alcoholic liver disease, and chronic liver disease of unknown etiology: report of the nationwide survey. J. Gastroenterol. 46:1230–37 [Google Scholar]
  35. Yasui K, Hashimoto E, Komorizono Y. 35.  et al. 2011. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin. Gastroenterol. Hepatol. 9:428–33 [Google Scholar]
  36. Ascha MS, Hanouneh IA, Lopez R. 36.  et al. 2010. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 51:1972–78 [Google Scholar]
  37. Kawamura Y, Arase Y, Ikeda K. 37.  et al. 2012. Large-scale long-term follow-up study of Japanese patients with nonalcoholic fatty liver disease for the onset of hepatocellular carcinoma. Am. J. Gastroenterol. 107:253–61 [Google Scholar]
  38. Tateishi R, Okanoue T, Fujiwara N. 38.  et al. 2015. Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multicenter cohort study. J. Gastroenterol. 50:350–60 [Google Scholar]
  39. Leung C, Yeoh SW, Patrick D. 39.  et al. 2015. Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-alcoholic fatty liver disease. World J. Gastroenterol. 21:1189–96 [Google Scholar]
  40. Vanni E, Bugianesi E. 40.  2014. Obesity and liver cancer. Clin. Liver. Dis. 18:191–203 [Google Scholar]
  41. Park EJ, Lee JH, Yu GY. 41.  et al. 2010. Dietary and genetic obesity promote liver inflammation and tumorigenesis enhancing IL-6 and TNF expression. Cell 140:197–208 [Google Scholar]
  42. Marra F, Bertolani C. 42.  2009. Adipokines in liver disease. Hepatology 50:957–69 [Google Scholar]
  43. Masson N, Ratcliffe PJ. 43.  2014. Hypoxia signaling pathways in cancer metabolism: the importance of co-selecting interconnected physiological pathways. Cancer Metab 2:3 http://www.cancerandmetabolism.com/content/2/1/3 [Google Scholar]
  44. Neuschwander-Tetri BA. 44.  2010. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 52:774–88 [Google Scholar]
  45. Zambo V, Simon-Szabo L, Szelenyi P. 45.  et al. 2013. Lipotoxicity in the liver. World J. Hepatol. 5:550–57 [Google Scholar]
  46. Wu J, Zhu AX. 46.  2011. Targeting insulin-like growth factor axis in hepatocellular carcinoma. J. Hematol. Oncol. 4:30 http://www.jhoonline.org/content/4/1/30 [Google Scholar]
  47. Laguna JC, Alegret M, Roglans N. 47.  2014. Simple sugar intake and hepatocellular carcinoma: epidemiological and mechanistic insight. Nutrients 6:5933–54 [Google Scholar]
  48. Yki-Jarvinen H. 48.  2010. Nutritional modulation of nonalcoholic fatty liver disease and insulin resistance: human data. Curr. Opin. Clin. Nutr. Metab. Care 13:709–14 [Google Scholar]
  49. Henao-Mejia J, Elinav E, Jin C. 49.  et al. 2012. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482:179–85 [Google Scholar]
  50. Yoshimoto S, Loo TM, Atarashi K. 50.  et al. 2013. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 499:97–101 [Google Scholar]
  51. Dongiovanni P, Romeo S, Valenti L. 51.  2014. Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors. World J. Gastroenterol. 20:12945–55 [Google Scholar]
  52. Shoelson SE, Herrero L, Naaz A. 52.  2007. Obesity, inflammation and insulin resistance. Gastroenterology 132:2169–80 [Google Scholar]
  53. Hirosumi J, Tuncman G, Chang L. 53.  et al. 2002. A central role for JNK in obesity and insulin resistance. Nature 420:333–36 [Google Scholar]
  54. Hodge DR, Hurt EM, Farrar WL. 54.  2005. The role of IL-6 and STAT3 in inflammation and cancer. Eur. J. Cancer 41:2502–12 [Google Scholar]
  55. Jiang N, Sun R, Sun Q. 55.  2014. Leptin signaling molecular actions and drug target in hepatocellular carcinoma. Drug Des. Dev. Ther. 8:2295–302 [Google Scholar]
  56. Villanueva A, Chiang DY, Newell P. 56.  et al. 2008. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 135:1972–83 [Google Scholar]
  57. Sharma D, Wang J, Fu PP. 57.  et al. 2010. Adiponectin antagonizes the oncogenic actions of leptin in hepatocellular carcinogenesis. Hepatology 52:1713–22 [Google Scholar]
  58. Donnelly KL, Smith CI, Schwarzenberg SJ. 58.  et al. 2005. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest. 115:1343–51 [Google Scholar]
  59. Ip BC, Liu C, Smith DE. 59.  et al. 2014. High-refined-carbohydrate and high-fat diets induce comparable hepatic tumorigenesis in male mice. J. Nutr. 144:647–53 [Google Scholar]
  60. Vos M, Lavine JE. 60.  2013. Dietary fructose in nonalcoholic fatty liver disease. Hepatology 57:2525–31 [Google Scholar]
  61. Romeo S, Kozlitina J, Xing C. 61.  et al. 2008. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 40:1461–65 [Google Scholar]
  62. Krawczyk M, Stokes CS, Romeo S, Lammert F. 62.  2015. HCC and liver disease risks in homozygous PNPLA3 p.I148M carriers approach monogenic inheritance. J. Hepatol. 62:980–81 [Google Scholar]
  63. Ertle J, Dechene A, Sowa JP. 63.  et al. 2010. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int. J. Cancer 128:2436–43 [Google Scholar]
  64. Mittal S, Sada YH, El-Serag HB. 64.  et al. 2015. Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the Veteran Affairs population. Clin. Gastroenterol. Hepatol. 13:594–601 [Google Scholar]
  65. Chen HP, Shieh JJ, Chang CC. 65.  et al. 2013. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut 62:606–15 [Google Scholar]
  66. Zhang H, Gao C, Fang L. 66.  et al. 2013. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis. Scand. J. Gastroenterol. 48:78–87 [Google Scholar]
  67. Singh S, Singh PP, Singh AJ. 67.  et al. 2013. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology 144:323–32 [Google Scholar]
  68. 68. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer 2012. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 56:908–43 [Google Scholar]
  69. Weinmann A, Alt Y, Koch S. 69.  et al. 2015. Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma. BMC Cancer 15:210 doi: 10.1186/s12885-015-1197-x [Google Scholar]
  70. Wong RJ, Cheung R, Ahmed A. 70.  2014. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology 59:2188–95 [Google Scholar]
  71. Wang X, Li J, Riaz DR. 71.  et al. 2014. Outcomes of liver transplantation for nonalcoholic steatohepatitis: a systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 12:394–402 [Google Scholar]
/content/journals/10.1146/annurev-med-090514-013832
Loading
/content/journals/10.1146/annurev-med-090514-013832
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error